We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.02 | -0.82% | 123.00 | 123.77 | 121.2902 | 123.06 | 5,932,928 | 01:00:00 |
PROFIT AND LOSS | 9M 2020 | 9M 2019 |
Growth
as reported |
Growth
at CER* |
|||||||||||||
DKK million | |||||||||||||||||
Net sales | 94,808 | 89,604 | 6 | % | 7 | % | |||||||||||
Operating profit | 42,948 | 40,610 | 6 | % | 7 | % | |||||||||||
Net profit | 32,820 | 30,234 | 9 | % | N/A | ||||||||||||
Diluted earnings per share (in DKK) | 14.00 | 12.68 | 10 | % | N/A |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 2 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 3 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 4 of 33
|
PROFIT AND LOSS | 9M 2020 | 9M 2019 | % change 9M 2020 to 9M 2019 | ||||||||||||||||||||||||||
(Amounts are in DKK million, except for earnings per share, dividend per share and employees) | |||||||||||||||||||||||||||||
Net sales | 94,808 | 89,604 | 6 | % | |||||||||||||||||||||||||
Gross profit | 79,495 | 74,948 | 6 | % | |||||||||||||||||||||||||
Gross margin | 83.8 | % | 83.6 | % | |||||||||||||||||||||||||
Sales and distribution costs | 23,162 | 22,287 | 4 | % | |||||||||||||||||||||||||
Percentage of sales | 24.4 | % | 24.9 | % | |||||||||||||||||||||||||
Research and development costs | 10,979 | 9,836 | 12 | % | |||||||||||||||||||||||||
Percentage of sales | 11.6 | % | 11.0 | % | |||||||||||||||||||||||||
Administrative costs | 2,760 | 2,772 | 0 | % | |||||||||||||||||||||||||
Percentage of sales | 2.9 | % | 3.1 | % | |||||||||||||||||||||||||
Other operating income, net | 354 | 557 | (36 | %) | |||||||||||||||||||||||||
Operating profit | 42,948 | 40,610 | 6 | % | |||||||||||||||||||||||||
Operating margin | 45.3% | 45.3% | |||||||||||||||||||||||||||
Financial items (net) | (1,820) | (3,136) | (42 | %) | |||||||||||||||||||||||||
Profit before income taxes | 41,128 | 37,474 | 10 | % | |||||||||||||||||||||||||
Income taxes | 8,308 | 7,240 | 15 | % | |||||||||||||||||||||||||
Effective tax rate | 20.2 | % | 19.3 | % | |||||||||||||||||||||||||
Net profit | 32,820 | 30,234 | 9 | % | |||||||||||||||||||||||||
Net profit margin | 34.6 | % | 33.7 | % | |||||||||||||||||||||||||
OTHER KEY NUMBERS | |||||||||||||||||||||||||||||
Depreciation, amortisation and impairment losses | 4,374 | 4,263 | 3 | % | |||||||||||||||||||||||||
Capital expenditure (Purchase of property, plant and equipment)1
|
4,307 | 7,025 | (39 | %) | |||||||||||||||||||||||||
Net cash generated from operating activities | 51,779 | 41,617 | 24 | % | |||||||||||||||||||||||||
Free cash flow | 41,559 | 32,714 | 27 | % | |||||||||||||||||||||||||
Total assets | 139,947 | 124,908 | 12 | % | |||||||||||||||||||||||||
Equity | 59,573 | 52,953 | 13 | % | |||||||||||||||||||||||||
Equity ratio | 42.6 | % | 42.4 | % | |||||||||||||||||||||||||
Average number of diluted shares outstanding (million) | 2,345.0 | 2,383.8 | (2 | %) | |||||||||||||||||||||||||
Diluted earnings per share / ADR (in DKK) | 14.00 | 12.68 | 10 | % | |||||||||||||||||||||||||
Full-time equivalent employees end of period | 44,326 | 42,158 | 5 | % | |||||||||||||||||||||||||
1) Cash-based capital expenditure.
|
|||||||||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 5 of 33
|
Sales split per geographical area |
Sales 9M 2020
DKK million |
Growth
as reported |
Growth
at CER |
Share of growth
at CER |
|||||||||||||
International Operations | 50,399 | 9 | % | 12 | % | 83 | % | ||||||||||
- EMEA | 26,159 | 9 | % | 11 | % | 39 | % | ||||||||||
- Region China | 10,836 | 10 | % | 12 | % | 19 | % | ||||||||||
- Rest of World | 13,404 | 8 | % | 13 | % | 25 | % | ||||||||||
North America Operations | 44,409 | 2 | % | 2 | % | 17 | % | ||||||||||
- The US | 41,947 | 2 | % | 2 | % | 11 | % | ||||||||||
Total sales | 94,808 | 6 | % | 7 | % | 100 | % |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 6 of 33
|
Sales split per therapy |
Sales 9M 2020
DKK million |
Sales 9M 2019
DKK million |
Growth
as reported |
Growth
at CER |
Share of growth
at CER |
||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||
Long-acting insulin | 13,426 | 15,674 | (14 | %) | (13 | %) | (33 | %) | |||||||||||||||
- Tresiba®
|
6,720 | 6,948 | (3 | %) | (2 | %) | (3 | %) | |||||||||||||||
- Xultophy®
|
1,842 | 1,626 | 13 | % | 15 | % | 4 | % | |||||||||||||||
- Levemir®
|
4,864 | 7,100 | (31 | %) | (30 | %) | (34 | %) | |||||||||||||||
Premix insulin | 8,220 | 7,913 | 4 | % | 6 | % | 8 | % | |||||||||||||||
- Ryzodeg®
|
967 | 747 | 29 | % | 33 | % | 4 | % | |||||||||||||||
- NovoMix®
|
7,253 | 7,166 | 1 | % | 3 | % | 4 | % | |||||||||||||||
Fast-acting insulin | 14,082 | 14,367 | (2 | %) | (1 | %) | (2 | %) | |||||||||||||||
- Fiasp®
|
1,021 | 804 | 27 | % | 28 | % | 3 | % | |||||||||||||||
- NovoRapid®
|
13,061 | 13,563 | (4 | %) | (2 | %) | (5 | %) | |||||||||||||||
Human insulin | 7,195 | 6,832 | 5 | % | 8 | % | 9 | % | |||||||||||||||
Total insulin | 42,923 | 44,786 | (4 | %) | (3 | %) | (18 | %) | |||||||||||||||
Victoza®
|
13,990 | 16,507 | (15 | %) | (15 | %) | (38 | %) | |||||||||||||||
Ozempic®
|
15,023 | 6,872 | 119 | % | 120 | % | 129 | % | |||||||||||||||
Rybelsus®
|
1,038 | — | — | — | 16 | % | |||||||||||||||||
Total GLP-1 | 30,051 | 23,379 | 29 | % | 29 | % | 107 | % | |||||||||||||||
Other Diabetes care1
|
3,056 | 3,230 | (5 | %) | (4 | %) | (2 | %) | |||||||||||||||
Total Diabetes care | 76,030 | 71,395 | 6 | % | 8 | % | 87 | % | |||||||||||||||
Obesity care (Saxenda®)
|
4,223 | 4,115 | 3 | % | 6 | % | 4 | % | |||||||||||||||
Diabetes and Obesity care total | 80,253 | 75,510 | 6 | % | 8 | % | 91 | % | |||||||||||||||
Biopharm segment | |||||||||||||||||||||||
Haemophilia2
|
7,522 | 7,727 | (3 | %) | (2 | %) | (2 | %) | |||||||||||||||
- NovoSeven®
|
5,683 | 6,160 | (8 | %) | (7 | %) | (7 | %) | |||||||||||||||
- NovoEight®
|
1,115 | 1,119 | 0 | % | 1 | % | 0 | % | |||||||||||||||
Growth disorders (Norditropin®)
|
5,872 | 5,199 | 13 | % | 13 | % | 11 | % | |||||||||||||||
Other Biopharm3
|
1,161 | 1,168 | (1 | %) | 1 | % | 0 | % | |||||||||||||||
Biopharm total | 14,555 | 14,094 | 3 | % | 4 | % | 9 | % | |||||||||||||||
Total sales | 94,808 | 89,604 | 6 | % | 7 | % | 100 | % | |||||||||||||||
1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
|
|||||||||||||||||||||||
2) Comprises NovoSeven®, NovoEight®, Refixia®, NovoThirteen® and Esperoct®.
|
|||||||||||||||||||||||
3) Primarily Vagifem® and Activelle®.
|
|||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 7 of 33
|
Diabetes care, development per area | Novo Nordisk’s share of the total diabetes market (value, MAT) | Diabetes care, sales development | |||||||||||||||
Aug | Aug |
Sales 9M 2020
DKK million |
Growth
at CER |
||||||||||||||
2020 | 2019 | ||||||||||||||||
Global | 29.2 | % | 28.4 | % | 76,030 | 8 | % | ||||||||||
International Operations | 22.7 | % | 22.0 | % | 39,768 | 13 | % | ||||||||||
- EMEA * | 27.4 | % | 26.8 | % | 20,076 | 11 | % | ||||||||||
- Region China ** | 28.5 | % | 27.8 | % | 10,526 | 12 | % | ||||||||||
- Rest of World *** | 13.3 | % | 12.7 | % | 9,166 | 17 | % | ||||||||||
North America Operations | 31.6 | % | 30.8 | % | 36,262 | 3 | % | ||||||||||
- The US | 31.7 | % | 31.1 | % | 34,396 | 2 | % | ||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 8 of 33
|
Insulin, development per geographical area | Novo Nordisk’s share of the total insulin market (volume, MAT) | Insulin, sales development | |||||||||||||||
Aug | Aug |
Sales 9M 2020
DKK million |
Growth
at CER |
||||||||||||||
2020 | 2019 | ||||||||||||||||
Global | 46.9 | % | 46.5 | % | 42,923 | (3 | %) | ||||||||||
International Operations | 49.7 | % | 49.1 | % | 29,431 | 10 | % | ||||||||||
- EMEA * | 47.2 | % | 46.5 | % | 13,982 | 6 | % | ||||||||||
- Region China ** | 49.5 | % | 50.2 | % | 8,523 | 14 | % | ||||||||||
- Rest of World *** | 57.0 | % | 56.0 | % | 6,926 | 12 | % | ||||||||||
North America Operations | 39.6 | % | 39.9 | % | 13,492 | (22 | %) | ||||||||||
- The US | 39.5 | % | 40.1 | % | 12,704 | (23 | %) | ||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 9 of 33
|
GLP-1, development per geographical area | Novo Nordisk's share of the diabetes GLP-1 market (value, MAT) | GLP-1, sales development | |||||||||||||||
Aug | Aug |
Sales 9M 2020
DKK million |
Growth
at CER |
||||||||||||||
2020 | 2019 | ||||||||||||||||
Global | 49.9 | % | 46.8 | % | 30,051 | 29 | % | ||||||||||
International Operations | 52.7 | % | 50.3 | % | 8,087 | 37 | % | ||||||||||
- EMEA * | 54.4 | % | 52.9 | % | 5,547 | 35 | % | ||||||||||
- Region China ** | 92.2 | % | 92.4 | % | 799 | 24 | % | ||||||||||
- Rest of World *** | 42.4 | % | 37.7 | % | 1,741 | 51 | % | ||||||||||
North America Operations | 49.4 | % | 46.3 | % | 21,964 | 27 | % | ||||||||||
- The US | 48.9 | % | 45.8 | % | 20,991 | 26 | % | ||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 10 of 33
|
Obesity care, development per geographical area | Obesity care, sales development | ||||||||||
Sales 9M 2020
DKK million |
Growth
at CER |
||||||||||
Global | 4,223 | 6 | % | ||||||||
International Operations | 1,611 | 8 | % | ||||||||
- EMEA | 834 | 8 | % | ||||||||
- Region China | 6 | (17 | %) | ||||||||
- Rest of World | 771 | 7 | % | ||||||||
North America Operations | 2,612 | 4 | % | ||||||||
- The US | 2,420 | 4 | % | ||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 11 of 33
|
Biopharm, development per geographical area | Biopharm, sales development | ||||||||||
Sales 9M 2020
DKK million |
Growth
at CER |
||||||||||
Global | 14,555 | 4 | % | ||||||||
International Operations | 9,020 | 8 | % | ||||||||
- EMEA | 5,249 | 10 | % | ||||||||
- Region China | 304 | 19 | % | ||||||||
- Rest of World | 3,467 | 5 | % | ||||||||
North America Operations | 5,535 | (2 | %) | ||||||||
- The US | 5,131 | (2 | %) | ||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 12 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 13 of 33
|
Sales split per geographical area |
Sales Q3 2020
DKK million |
Growth
as reported |
Growth
at CER |
Share of growth
at CER |
|||||||||||||
International Operations | 15,988 | 5 | % | 10 | % | 70 | % | ||||||||||
- EMEA | 8,318 | 5 | % | 9 | % | 30 | % | ||||||||||
- Region China | 3,549 | 9 | % | 13 | % | 19 | % | ||||||||||
- Rest of World | 4,121 | 1 | % | 11 | % | 21 | % | ||||||||||
North America Operations | 14,939 | (1 | %) | 5 | % | 30 | % | ||||||||||
- The US | 14,144 | (1 | %) | 4 | % | 26 | % | ||||||||||
Total sales | 30,927 | 2 | % | 7 | % | 100 | % |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 14 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 15 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
|
|
|
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 16 of 33
|
Expectations are as reported, if not otherwise stated |
Expectations
30 October 2020 |
Expectations
6 August 2020 |
||||||
Sales growth | ||||||||
at CER | 5% to 8% | 3% to 6% | ||||||
as reported | Around 3 percentage points lower than at CER | Around 2 percentage points lower than at CER | ||||||
Operating profit growth | ||||||||
at CER | 5% to 8% | 2% to 5% | ||||||
as reported | Around 4 percentage points lower than at CER | Around 3 percentage points lower than at CER | ||||||
Financial items (net) | Loss of around DKK 1.4 billion | Loss of around DKK 1.2 billion | ||||||
Effective tax rate | 20% to 22% | 20% to 22% | ||||||
Capital expenditure (PP&E) | Around DKK 6.5 billion | Around DKK 6.5 billion | ||||||
Depreciation, amortisation and impairment losses | Around DKK 5.5 billion | Around DKK 5 billion | ||||||
Free cash flow | DKK 34-39 billion | DKK 33-38 billion | ||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 17 of 33
|
FX | Q3 2020 | Q3 2019 | % change | 9M 2020 | 9M 2019 | % change |
Spot rate
26 October 2020 |
||||||||||||||||
USD | 637 | 671 | (5 | %) | 663 | 664 | 0 | % | 630 | ||||||||||||||
CNY | 92 | 96 | (4 | %) | 95 | 97 | (2 | %) | 94 | ||||||||||||||
JPY | 6.00 | 6.26 | (4 | %) | 6.17 | 6.09 | 1 | % | 5.99 | ||||||||||||||
CAD | 478 | 508 | (6 | %) | 491 | 500 | (2 | %) | 478 | ||||||||||||||
GBP | 823 | 827 | 0 | % | 843 | 845 | 0 | % | 820 | ||||||||||||||
Key invoicing currencies | Impact on Novo Nordisk's operating profit in the next 12 months of a 5% movement in currency | Hedging period (months) | ||||||
USD | DKK 1,900 million | 11 | ||||||
CNY1
|
DKK 450 million | 6 | ||||||
JPY | DKK 150 million | 12 | ||||||
CAD | DKK 130 million | 9 | ||||||
GBP | DKK 100 million | 10 | ||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 18 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 19 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Corporate governance | Legal | Financial Information | ||||||||||||||||||
Company announcement No XX / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Corporate governance | Legal | Financial Information | ||||||||||||||||||
Company announcement No XX / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Corporate governance | Legal | Financial Information | ||||||||||||||||||
Company announcement No XX / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Corporate governance | Legal | Financial Information | ||||||||||||||||||
Company announcement No XX / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Corporate governance | Legal | Financial Information | ||||||||||||||||||
Company announcement No XX / 2020 |
Financial Performance | Equity | Outlook | Strategic aspirations | R&D | Sustainability | Legal | Financial Information | |||||||||||||||||||
Company announcement No XX / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 20 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 21 of 33
|
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 22 of 33
|
Financial calendar | |||||
03 February 2021 | Financial statement for 2020 | ||||
25 March 2021 | Annual General Meeting | ||||
5 May 2021 | Financial statement for the first three month of 2021 | ||||
5 August 2021 | Financial statement for the first six month of 2021 | ||||
3 November 2021 | Financial statement for the first nine month of 2021 |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 23 of 33
|
(Amounts in DKK million, except number of full-time equivalent employees, earnings per share and number of shares outstanding). | |||||||||||||||||||||||||||||||||||
% change | |||||||||||||||||||||||||||||||||||
2020 | 2019 | Q3 2020 vs. | |||||||||||||||||||||||||||||||||
Q3 | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | Q3 2019 | ||||||||||||||||||||||||||||
Net sales | 30,927 | 30,006 | 33,875 | 32,417 | 30,277 | 30,036 | 29,291 | 2 | % | ||||||||||||||||||||||||||
Gross profit | 25,772 | 25,234 | 28,489 | 26,985 | 25,202 | 25,187 | 24,559 | 2 | % | ||||||||||||||||||||||||||
Gross margin | 83.3% | 84.1% | 84.1% | 83.2% | 83.2% | 83.9% | 83.8% | ||||||||||||||||||||||||||||
Sales and distribution costs | 8,174 | 7,398 | 7,590 | 9,536 | 7,761 | 7,580 | 6,946 | 5 | % | ||||||||||||||||||||||||||
Percentage of sales | 26.4% | 24.7% | 22.4% | 29.4% | 25.6% | 25.2% | 23.7% | ||||||||||||||||||||||||||||
Research and development costs | 3,911 | 3,291 | 3,777 | 4,384 | 3,601 | 3,557 | 2,678 | 9 | % | ||||||||||||||||||||||||||
Percentage of sales | 12.6% | 11.0% | 11.1% | 13.5% | 11.9% | 11.8% | 9.1% | ||||||||||||||||||||||||||||
Administrative costs | 1,006 | 827 | 927 | 1,235 | 1,009 | 852 | 911 | 0 | % | ||||||||||||||||||||||||||
Percentage of sales | 3.3% | 2.8% | 2.7% | 3.8% | 3.3% | 2.8% | 3.1% | ||||||||||||||||||||||||||||
Other operating income, net | 127 | 120 | 107 | 43 | 88 | 254 | 215 | 44 | % | ||||||||||||||||||||||||||
Operating profit | 12,808 | 13,838 | 16,302 | 11,873 | 12,919 | 13,452 | 14,239 | (1 | %) | ||||||||||||||||||||||||||
Operating margin | 41.4% | 46.1% | 48.1% | 36.6% | 42.7% | 44.8% | 48.6% | ||||||||||||||||||||||||||||
Financial income | 162 | 97 | 17 | 20 | 17 | 15 | 13 | N/A | |||||||||||||||||||||||||||
Financial expenses | 279 | 519 | 1,298 | 814 | 829 | 1,322 | 1,030 | (66 | %) | ||||||||||||||||||||||||||
Financial items (net) | (117) | (422) | (1,281) | (794) | (812) | (1,307) | (1,017) | (86 | %) | ||||||||||||||||||||||||||
Profit before income taxes | 12,691 | 13,416 | 15,021 | 11,079 | 12,107 | 12,145 | 13,222 | 5 | % | ||||||||||||||||||||||||||
Income taxes | 2,393 | 2,791 | 3,124 | 2,362 | 1,913 | 2,550 | 2,777 | 25 | % | ||||||||||||||||||||||||||
Net profit | 10,298 | 10,625 | 11,897 | 8,717 | 10,194 | 9,595 | 10,445 | 1 | % | ||||||||||||||||||||||||||
Depreciation, amortisation and
impairment losses |
2,130 | 1,158 | 1,086 | 1,398 | 2,095 | 1,110 | 1,058 | 2 | % | ||||||||||||||||||||||||||
Capital expenditure1
|
1,401 | 1,239 | 1,667 | 1,907 | 2,234 | 2,147 | 2,644 | (37 | %) | ||||||||||||||||||||||||||
Net cash generated from operating activities | 17,506 | 24,261 | 10,012 | 5,165 | 16,688 | 15,039 | 9,890 | 5 | % | ||||||||||||||||||||||||||
Free cash flow | 11,224 | 22,666 | 7,669 | 1,737 | 14,039 | 12,020 | 6,655 | (20 | %) | ||||||||||||||||||||||||||
Total assets | 139,947 | 136,121 | 126,256 | 125,612 | 124,908 | 117,909 | 110,135 | 12 | % | ||||||||||||||||||||||||||
Total equity | 59,573 | 60,054 | 54,399 | 57,593 | 52,953 | 53,085 | 47,319 | 13 | % | ||||||||||||||||||||||||||
Equity ratio | 42.6% | 44.1% | 43.1% | 45.8% | 42.4% | 45.0% | 43.0% | ||||||||||||||||||||||||||||
Full-time equivalent employees end of period | 44,326 | 43,526 | 43,158 | 42,703 | 42,158 | 41,611 | 42,453 | 5 | % | ||||||||||||||||||||||||||
Basic earnings per share/ADR (in DKK) | 4.42 | 4.54 | 5.07 | 3.71 | 4.3 | 4.03 | 4.37 | 3 | % | ||||||||||||||||||||||||||
Diluted earnings per share/ADR (in DKK) | 4.42 | 4.53 | 5.05 | 3.70 | 4.29 | 4.03 | 4.36 | 3 | % | ||||||||||||||||||||||||||
Average number of shares outstanding (million) | 2,329.0 | 2,338.8 | 2,348.8 | 2,357.9 | 2,368.8 | 2,380.2 | 2,390.3 | (2 | %) | ||||||||||||||||||||||||||
Average number of diluted shares | |||||||||||||||||||||||||||||||||||
outstanding (million) | 2,335.1 | 2,344.9 | 2,354.8 | 2,363.3 | 2,373.2 | 2,383.5 | 2,394.6 | (2 | %) | ||||||||||||||||||||||||||
Sales by business segment: | |||||||||||||||||||||||||||||||||||
Long-acting insulin | 4,048 | 4,220 | 5,158 | 5,102 | 5,019 | 5,411 | 5,244 | (19 | %) | ||||||||||||||||||||||||||
Premix insulin | 2,572 | 2,693 | 2,955 | 2,665 | 2,596 | 2,560 | 2,757 | (1 | %) | ||||||||||||||||||||||||||
Fast-acting insulin | 4,589 | 4,379 | 5,114 | 4,936 | 4,632 | 4,758 | 4,977 | (1 | %) | ||||||||||||||||||||||||||
Human insulin | 2,194 | 2,314 | 2,687 | 2,204 | 2,237 | 2,180 | 2,415 | (2 | %) | ||||||||||||||||||||||||||
Total insulin | 13,403 | 13,606 | 15,914 | 14,907 | 14,484 | 14,909 | 15,393 | (7 | %) | ||||||||||||||||||||||||||
Total GLP-1 | 10,651 | 9,425 | 9,975 | 9,842 | 8,492 | 7,740 | 7,147 | 25 | % | ||||||||||||||||||||||||||
Other Diabetes care | 954 | 977 | 1,125 | 1,017 | 1,038 | 1,125 | 1,067 | (8 | %) | ||||||||||||||||||||||||||
Total Diabetes care | 25,008 | 24,008 | 27,014 | 25,766 | 24,014 | 23,774 | 23,607 | 4 | % | ||||||||||||||||||||||||||
Obesity care (Saxenda®)
|
1,338 | 1,308 | 1,577 | 1,564 | 1,442 | 1,462 | 1,211 | (7 | %) | ||||||||||||||||||||||||||
Diabetes and Obesity care total | 26,346 | 25,316 | 28,591 | 27,330 | 25,456 | 25,236 | 24,818 | 3 | % | ||||||||||||||||||||||||||
Haemophilia | 2,311 | 2,401 | 2,810 | 2,554 | 2,524 | 2,670 | 2,533 | (8 | %) | ||||||||||||||||||||||||||
Growth disorders (Norditropin®)
|
1,890 | 1,952 | 2,030 | 2,076 | 1,886 | 1,758 | 1,555 | 0 | % | ||||||||||||||||||||||||||
Other Biopharm | 380 | 337 | 444 | 457 | 411 | 372 | 385 | (8 | %) | ||||||||||||||||||||||||||
Biopharm total | 4,581 | 4,690 | 5,284 | 5,087 | 4,821 | 4,800 | 4,473 | (5 | %) | ||||||||||||||||||||||||||
Sales by geographic segment: | |||||||||||||||||||||||||||||||||||
International Operations2
|
15,988 | 16,115 | 18,296 | 15,351 | 15,261 | 15,565 | 15,387 | 5 | % | ||||||||||||||||||||||||||
- EMEA | 8,318 | 8,167 | 9,674 | 8,231 | 7,913 | 8,120 | 7,944 | 5 | % | ||||||||||||||||||||||||||
- Region China | 3,549 | 3,474 | 3,813 | 3,019 | 3,258 | 3,192 | 3,375 | 9 | % | ||||||||||||||||||||||||||
- Rest of World | 4,121 | 4,474 | 4,809 | 4,101 | 4,090 | 4,253 | 4,068 | 1 | % | ||||||||||||||||||||||||||
North America Operations | 14,939 | 13,891 | 15,579 | 17,066 | 15,016 | 14,471 | 13,904 | (1 | %) | ||||||||||||||||||||||||||
- The US | 14,144 | 13,028 | 14,775 | 16,252 | 14,256 | 13,767 | 13,211 | (1 | %) | ||||||||||||||||||||||||||
Segment operating profit: | |||||||||||||||||||||||||||||||||||
Diabetes and Obesity care | 9,748 | 11,434 | 13,456 | 9,013 | 10,403 | 11,393 | 11,828 | (6 | %) | ||||||||||||||||||||||||||
Biopharm | 3,060 | 2,404 | 2,846 | 2,860 | 2,516 | 2,059 | 2,411 | 22 | % | ||||||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 24 of 33
|
DKK million | 9M 2020 | 9M 2019 | Q3 2020 | Q3 2019 | |||||||||||||||||||
Income statement | |||||||||||||||||||||||
Net sales | 94,808 | 89,604 | 30,927 | 30,277 | |||||||||||||||||||
Cost of goods sold | 15,313 | 14,656 | 5,155 | 5,075 | |||||||||||||||||||
Gross profit | 79,495 | 74,948 | 25,772 | 25,202 | |||||||||||||||||||
Sales and distribution costs | 23,162 | 22,287 | 8,174 | 7,761 | |||||||||||||||||||
Research and development costs | 10,979 | 9,836 | 3,911 | 3,601 | |||||||||||||||||||
Administrative costs | 2,760 | 2,772 | 1,006 | 1,009 | |||||||||||||||||||
Other operating income, net | 354 | 557 | 127 | 88 | |||||||||||||||||||
Operating profit | 42,948 | 40,610 | 12,808 | 12,919 | |||||||||||||||||||
Financial income | 276 | 45 | 162 | 17 | |||||||||||||||||||
Financial expenses | 2,096 | 3,181 | 279 | 829 | |||||||||||||||||||
Profit before income taxes | 41,128 | 37,474 | 12,691 | 12,107 | |||||||||||||||||||
Income taxes | 8,308 | 7,240 | 2,393 | 1,913 | |||||||||||||||||||
NET PROFIT | 32,820 | 30,234 | 10,298 | 10,194 | |||||||||||||||||||
Basic earnings per share (DKK) | 14.03 | 12.70 | 4.42 | 4.30 | |||||||||||||||||||
Diluted earnings per share (DKK) | 14.00 | 12.68 | 4.42 | 4.29 | |||||||||||||||||||
Segment Information | |||||||||||||||||||||||
Segment sales: | |||||||||||||||||||||||
Diabetes and Obesity care | 80,253 | 75,510 | 26,346 | 25,456 | |||||||||||||||||||
Biopharm | 14,555 | 14,094 | 4,581 | 4,821 | |||||||||||||||||||
Segment operating profit: | |||||||||||||||||||||||
Diabetes and Obesity care | 34,638 | 33,624 | 9,748 | 10,403 | |||||||||||||||||||
Operating margin | 43.2% | 44.5% | 37.0% | 40.9% | |||||||||||||||||||
Biopharm | 8,310 | 6,986 | 3,060 | 2,516 | |||||||||||||||||||
Operating margin | 57.1% | 49.6% | 66.8% | 52.2% | |||||||||||||||||||
Total segment operating profit | 42,948 | 40,610 | 12,808 | 12,919 | |||||||||||||||||||
Statement of comprehensive income | |||||||||||||||||||||||
Net profit for the period | 32,820 | 30,234 | 10,298 | 10,194 | |||||||||||||||||||
Other comprehensive income | |||||||||||||||||||||||
Items that will not subsequently be reclassified to the Income
statement |
|||||||||||||||||||||||
Remeasurements on defined benefit plans | 27 | (369) | (77) | (167) | |||||||||||||||||||
Items that will be reclassified subsequently to the Income
statement |
|||||||||||||||||||||||
Exchange rate adjustments of investments in subsidiaries | (1,002) | 489 | (788) | 305 | |||||||||||||||||||
Cash flow hedges, realisation of previously deferred (gains)/losses | 343 | 1,686 | (65) | 202 | |||||||||||||||||||
Cash flow hedges, deferred gains/(losses) incurred during the period | 1,019 | (1,405) | 606 | (1,006) | |||||||||||||||||||
Other items | 4 | 10 | 1 | (6) | |||||||||||||||||||
Tax on other comprehensive income, income/(expense) | (512) | 25 | (169) | 212 | |||||||||||||||||||
Other comprehensive income for the period, net of tax | (121) | 436 | (492) | (460) | |||||||||||||||||||
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | 32,699 | 30,670 | 9,806 | 9,734 | |||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 25 of 33
|
DKK million | 9M 2020 | 9M 2019 | |||||||||
Net profit | 32,820 | 30,234 | |||||||||
Adjustment for non-cash items: | |||||||||||
Income taxes in the Income Statement | 8,308 | 7,240 | |||||||||
Depreciation, amortisation and impairment losses | 4,374 | 4,263 | |||||||||
Other non-cash items | 13,508 | 7,139 | |||||||||
Change in working capital | (384) | (1,304) | |||||||||
Interest received | 50 | 45 | |||||||||
Interest paid | (182) | (148) | |||||||||
Income taxes paid | (6,715) | (5,852) | |||||||||
Net cash generated from operating activities | 51,779 | 41,617 | |||||||||
Purchase of intangible assets | (4,869) | (1,238) | |||||||||
Proceeds from sale of property, plant and equipment | 3 | 2 | |||||||||
Purchase of property, plant and equipment | (4,307) | (7,025) | |||||||||
Proceeds from other financial assets | 11 | — | |||||||||
Purchase of other financial assets | — | (6) | |||||||||
Investment in associated company | (392) | (50) | |||||||||
Proceeds from the divestment of Group and associated companies | — | (3) | |||||||||
Dividend received from associated company | 18 | 20 | |||||||||
Net cash used in investing activities | (9,536) | (8,300) | |||||||||
Purchase of treasury shares | (11,195) | (10,404) | |||||||||
Dividends paid | (20,121) | (19,409) | |||||||||
Repayment of borrowings, net | (568) | (470) | |||||||||
Net cash used in financing activities | (31,884) | (30,283) | |||||||||
NET CASH GENERATED FROM ACTIVITIES | 10,359 | 3,034 | |||||||||
Cash and cash equivalents at the beginning of the year | 15,411 | 15,629 | |||||||||
Exchange gain/(loss) on cash and cash equivalents | (305) | 93 | |||||||||
Cash and cash equivalents at the end of the period | 25,465 | 18,756 | |||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 26 of 33
|
DKK million | 30 Sep 2020 | 31 Dec 2019 | |||||||||
ASSETS | |||||||||||
Intangible assets | 9,415 | 5,835 | |||||||||
Property, plant and equipment | 49,925 | 50,551 | |||||||||
Investments in associated companies | 601 | 474 | |||||||||
Deferred income tax assets | 4,745 | 4,121 | |||||||||
Other receivables and prepayments | 562 | 841 | |||||||||
Other financial assets | 1,032 | 1,334 | |||||||||
TOTAL NON-CURRENT ASSETS | 66,280 | 63,156 | |||||||||
Inventories | 18,105 | 17,641 | |||||||||
Trade receivables | 24,358 | 24,912 | |||||||||
Tax receivables | 423 | 806 | |||||||||
Other receivables and prepayments | 3,613 | 3,434 | |||||||||
Derivative financial instruments | 1,688 | 188 | |||||||||
Cash at bank | 25,480 | 15,475 | |||||||||
TOTAL CURRENT ASSETS | 73,667 | 62,456 | |||||||||
TOTAL ASSETS | 139,947 | 125,612 | |||||||||
EQUITY AND LIABILITIES | |||||||||||
Share capital | 470 | 480 | |||||||||
Treasury shares | (5) | (10) | |||||||||
Retained earnings | 59,850 | 57,817 | |||||||||
Other reserves | (742) | (694) | |||||||||
TOTAL EQUITY | 59,573 | 57,593 | |||||||||
Borrowings | 2,636 | 3,009 | |||||||||
Deferred income tax liabilities | 991 | 80 | |||||||||
Retirement benefit obligations | 1,324 | 1,334 | |||||||||
Provisions | 4,475 | 4,613 | |||||||||
Total non-current liabilities | 9,426 | 9,036 | |||||||||
Borrowings | 1,468 | 1,474 | |||||||||
Trade payables | 6,123 | 6,358 | |||||||||
Tax payables | 5,019 | 4,212 | |||||||||
Other liabilities | 15,298 | 15,085 | |||||||||
Derivative financial instruments | 1,002 | 734 | |||||||||
Provisions | 42,038 | 31,120 | |||||||||
Total current liabilities | 70,948 | 58,983 | |||||||||
TOTAL LIABILITIES | 80,374 | 68,019 | |||||||||
TOTAL EQUITY AND LIABILITIES | 139,947 | 125,612 |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 27 of 33
|
Other reserves | |||||||||||||||||||||||||||||
DKK million |
Share
capital |
Treasury
shares |
Retained
earnings |
Exchange
rate adjust-ments |
Cash
flow hedges |
Tax and
other adjust-ments |
Total
other reserves |
Total | |||||||||||||||||||||
9M 2020 | |||||||||||||||||||||||||||||
Balance at the beginning of the period | 480 | (10) | 57,817 | (839) | (329) | 474 | (694) | 57,593 | |||||||||||||||||||||
Net profit for the period | 32,820 | 32,820 | |||||||||||||||||||||||||||
Other comprehensive income for the period | 27 | (1,002) | 1,362 | (508) | (148) | (121) | |||||||||||||||||||||||
Total comprehensive income for the period | 32,847 | (1,002) | 1,362 | (508) | (148) | 32,699 | |||||||||||||||||||||||
Transfer of cash flow hedge reserve to intangible assets | 128 | (28) | 100 | 100 | |||||||||||||||||||||||||
Transactions with owners: | |||||||||||||||||||||||||||||
Dividends | (20,121) | (20,121) | |||||||||||||||||||||||||||
Share-based payments | 468 | 468 | |||||||||||||||||||||||||||
Tax related to restricted stock units | 29 | 29 | |||||||||||||||||||||||||||
Purchase of treasury shares | (5) | (11,190) | (11,195) | ||||||||||||||||||||||||||
Reduction of the B share capital | (10) | 10 | — | ||||||||||||||||||||||||||
Balance at the end of the period | 470 | (5) | 59,850 | (1,841) | 1,161 | (62) | (742) | 59,573 | |||||||||||||||||||||
Other reserves | |||||||||||||||||||||||||||||
DKK million |
Share
capital |
Treasury
shares |
Retained
earnings |
Exchange
rate adjust-ments |
Cash
flow hedges |
Tax and
other adjust-ments |
Total
other reserves |
Total | |||||||||||||||||||||
9M 2019 | |||||||||||||||||||||||||||||
Balance at the beginning of the period | 490 | (11) | 53,406 | (1,065) | (1,677) | 696 | (2,046) | 51,839 | |||||||||||||||||||||
Net profit for the period | 30,234 | 30,234 | |||||||||||||||||||||||||||
Other comprehensive income for the period | (369) | 489 | 281 | 35 | 805 | 436 | |||||||||||||||||||||||
Total comprehensive income for the period | 29,865 | 489 | 281 | 35 | 805 | 30,670 | |||||||||||||||||||||||
Transactions with owners: | |||||||||||||||||||||||||||||
Dividends | (19,409) | (19,409) | |||||||||||||||||||||||||||
Share-based payments | 245 | 245 | |||||||||||||||||||||||||||
Tax related to restricted stock units | 12 | 12 | |||||||||||||||||||||||||||
Purchase of treasury shares | (6) | (10,398) | (10,404) | ||||||||||||||||||||||||||
Reduction of the B share capital | (10) | 10 | — | ||||||||||||||||||||||||||
Balance at the end of the period | 480 | (7) | 53,721 | (576) | (1,396) | 731 | (1,241) | 52,953 | |||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 28 of 33
|
Q3 2020 sales split per area | |||||||||||||||||||||||||||||
DKK million | Total |
International
Operations |
EMEA |
Region
China |
Rest of
World |
North America
Operations |
The US | ||||||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||||||||
Long-acting insulin | 4,048 | 2,460 | 1,577 | 399 | 484 | 1,588 | 1,467 | ||||||||||||||||||||||
% change at CER | (15%) | 14% | 14% | 43% | (1%) | (38%) | (40%) | ||||||||||||||||||||||
Tresiba®
|
2,102 | 1,126 | 652 | 139 | 335 | 976 | 887 | ||||||||||||||||||||||
% change at CER | (4%) | 33% | 37% | — | (1%) | (27%) | (30%) | ||||||||||||||||||||||
Xultophy®
|
604 | 443 | 405 | — | 38 | 161 | 158 | ||||||||||||||||||||||
% change at CER | 9% | 24% | 20% | — | 70% | (17%) | (18%) | ||||||||||||||||||||||
Levemir®
|
1,342 | 891 | 520 | 260 | 111 | 451 | 422 | ||||||||||||||||||||||
% change at CER | (33%) | (6%) | (9%) | 3% | (14%) | (57%) | (58%) | ||||||||||||||||||||||
Premix insulin | 2,572 | 2,447 | 645 | 1,201 | 601 | 125 | 119 | ||||||||||||||||||||||
% change at CER | 4% | 4% | (11%) | 14% | 6% | 12% | 15% | ||||||||||||||||||||||
Ryzodeg®
|
296 | 296 | 79 | 13 | 204 | — | — | ||||||||||||||||||||||
% change at CER | 15% | 15% | 30% | — | 3% | — | — | ||||||||||||||||||||||
NovoMix®
|
2,276 | 2,151 | 566 | 1,188 | 397 | 125 | 119 | ||||||||||||||||||||||
% change at CER | 3% | 3% | (15%) | 13% | 7% | 12% | 15% | ||||||||||||||||||||||
Fast-acting insulin | 4,589 | 2,611 | 1,562 | 508 | 541 | 1,978 | 1,883 | ||||||||||||||||||||||
% change at CER | 4% | 8% | 7% | 14% | 6% | (1%) | (1%) | ||||||||||||||||||||||
Fiasp®
|
345 | 201 | 186 | — | 15 | 144 | 136 | ||||||||||||||||||||||
% change at CER | 18% | 24% | 25% | — | 21% | 10% | 11% | ||||||||||||||||||||||
NovoRapid®
|
4,244 | 2,410 | 1,376 | 508 | 526 | 1,834 | 1,747 | ||||||||||||||||||||||
% change at CER | 3% | 7% | 5% | 14% | 6% | (2%) | (1%) | ||||||||||||||||||||||
Human insulin | 2,194 | 1,774 | 551 | 696 | 527 | 420 | 397 | ||||||||||||||||||||||
% change at CER | 5% | 5% | (7%) | 2% | 25% | 1% | 3% | ||||||||||||||||||||||
Total insulin | 13,403 | 9,292 | 4,335 | 2,804 | 2,153 | 4,111 | 3,866 | ||||||||||||||||||||||
% change at CER | (2%) | 8% | 4% | 14% | 8% | (20%) | (20%) | ||||||||||||||||||||||
Victoza®
|
4,765 | 1,817 | 1,057 | 294 | 466 | 2,948 | 2,863 | ||||||||||||||||||||||
% change at CER | (7%) | 8% | (7%) | 33% | 43% | (15%) | (15%) | ||||||||||||||||||||||
Ozempic®
|
5,432 | 892 | 765 | 2 | 125 | 4,540 | 4,295 | ||||||||||||||||||||||
% change at CER | 82% | 188% | 171% | — | 302% | 70% | 69% | ||||||||||||||||||||||
Rybelsus®
|
454 | 16 | 16 | — | — | 438 | 437 | ||||||||||||||||||||||
% change at CER | — | — | — | — | — | — | — | ||||||||||||||||||||||
Total GLP-1 | 10,651 | 2,725 | 1,838 | 296 | 591 | 7,926 | 7,595 | ||||||||||||||||||||||
% change at CER | 31% | 37% | 29% | 35% | 70% | 29% | 29% | ||||||||||||||||||||||
Other Diabetes care1
|
954 | 730 | 179 | 389 | 162 | 224 | 190 | ||||||||||||||||||||||
% change at CER | (4%) | (7%) | (28%) | 3% | 2% | 9% | 13% | ||||||||||||||||||||||
Total Diabetes care | 25,008 | 12,747 | 6,352 | 3,489 | 2,906 | 12,261 | 11,651 | ||||||||||||||||||||||
% change at CER | 9% | 12% | 9% | 14% | 17% | 7% | 6% | ||||||||||||||||||||||
Obesity care (Saxenda®)
|
1,338 | 485 | 258 | 2 | 225 | 853 | 794 | ||||||||||||||||||||||
% change at CER | 0% | 6% | 14% | (50%) | 0% | (3%) | (3%) | ||||||||||||||||||||||
Diabetes and Obesity care total | 26,346 | 13,232 | 6,610 | 3,491 | 3,131 | 13,114 | 12,445 | ||||||||||||||||||||||
% change at CER | 9% | 12% | 9% | 14% | 15% | 6% | 6% | ||||||||||||||||||||||
Biopharm segment | |||||||||||||||||||||||||||||
Haemophilia2
|
2,311 | 1,345 | 974 | 44 | 327 | 966 | 910 | ||||||||||||||||||||||
% change at CER | (4%) | (2%) | 8% | (40%) | (17%) | (6%) | (6%) | ||||||||||||||||||||||
NovoSeven®
|
1,674 | 891 | 627 | 40 | 224 | 783 | 763 | ||||||||||||||||||||||
% change at CER | (11%) | (13%) | (3%) | (42%) | (27%) | (8%) | (9%) | ||||||||||||||||||||||
NovoEight®
|
375 | 287 | 213 | 4 | 70 | 88 | 83 | ||||||||||||||||||||||
% change at CER | 10% | 12% | 6% | 0% | 33% | 3% | 6% | ||||||||||||||||||||||
Growth disorders (Norditropin®)
|
1,890 | 1,143 | 519 | 13 | 611 | 747 | 741 | ||||||||||||||||||||||
% change at CER | 5% | 14% | 16% | 40% | 12% | (6%) | (7%) | ||||||||||||||||||||||
Other Biopharm3
|
380 | 268 | 215 | 1 | 52 | 112 | 48 | ||||||||||||||||||||||
% change at CER | (5%) | (6%) | (6%) | (100%) | (4%) | (2%) | (15%) | ||||||||||||||||||||||
Biopharm total | 4,581 | 2,756 | 1,708 | 58 | 990 | 1,825 | 1,699 | ||||||||||||||||||||||
% change at CER | 0% | 4% | 8% | (31%) | 0% | (6%) | (7%) | ||||||||||||||||||||||
Total sales | 30,927 | 15,988 | 8,318 | 3,549 | 4,121 | 14,939 | 14,144 | ||||||||||||||||||||||
% change at CER | 7% | 10% | 9% | 13% | 11% | 5% | 4% | ||||||||||||||||||||||
% change as reported | 2% | 5% | 5% | 9% | 1% | (1%) | (1%) | ||||||||||||||||||||||
Share of growth | 100% | 70% | 30% | 19% | 21% | 30% | 26% |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 29 of 33
|
9M 2020 sales split per area | |||||||||||||||||||||||||||||
DKK million | Total |
International
Operations |
EMEA |
Region
China |
Rest of
World |
North America
Operations |
The US | ||||||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||||||||
Long-acting insulin | 13,426 | 7,590 | 4,916 | 1,120 | 1,554 | 5,836 | 5,452 | ||||||||||||||||||||||
% change at CER | (13%) | 14% | 12% | 39% | 8% | (34%) | (36%) | ||||||||||||||||||||||
Tresiba®
|
6,720 | 3,345 | 1,957 | 300 | 1,088 | 3,375 | 3,101 | ||||||||||||||||||||||
% change at CER | (2%) | 31% | 32% | — | 8% | (22%) | (26%) | ||||||||||||||||||||||
Xultophy®
|
1,842 | 1,326 | 1,209 | 1 | 116 | 516 | 508 | ||||||||||||||||||||||
% change at CER | 15% | 25% | 19% | — | 125% | (5%) | (6%) | ||||||||||||||||||||||
Levemir®
|
4,864 | 2,919 | 1,750 | 819 | 350 | 1,945 | 1,843 | ||||||||||||||||||||||
% change at CER | (30%) | (4%) | (8%) | 9% | (9%) | (51%) | (52%) | ||||||||||||||||||||||
Premix insulin | 8,220 | 7,799 | 2,275 | 3,662 | 1,862 | 421 | 401 | ||||||||||||||||||||||
% change at CER | 6% | 8% | (1%) | 13% | 11% | (22%) | (22%) | ||||||||||||||||||||||
Ryzodeg®
|
967 | 967 | 252 | 26 | 689 | — | — | ||||||||||||||||||||||
% change at CER | 33% | 33% | 47% | — | 25% | — | — | ||||||||||||||||||||||
NovoMix®
|
7,253 | 6,832 | 2,023 | 3,636 | 1,173 | 421 | 401 | ||||||||||||||||||||||
% change at CER | 3% | 5% | (5%) | 13% | 5% | (22%) | (22%) | ||||||||||||||||||||||
Fast-acting insulin | 14,082 | 8,170 | 4,968 | 1,563 | 1,639 | 5,912 | 5,604 | ||||||||||||||||||||||
% change at CER | (1%) | 8% | 6% | 18% | 5% | (11%) | (12%) | ||||||||||||||||||||||
Fiasp®
|
1,021 | 591 | 547 | — | 44 | 430 | 404 | ||||||||||||||||||||||
% change at CER | 28% | 34% | 32% | — | 68% | 19% | 19% | ||||||||||||||||||||||
NovoRapid®
|
13,061 | 7,579 | 4,421 | 1,563 | 1,595 | 5,482 | 5,200 | ||||||||||||||||||||||
% change at CER | (2%) | 6% | 3% | 18% | 4% | (13%) | (13%) | ||||||||||||||||||||||
Human insulin | 7,195 | 5,872 | 1,823 | 2,178 | 1,871 | 1,323 | 1,247 | ||||||||||||||||||||||
% change at CER | 8% | 8% | 0% | 2% | 25% | 10% | 12% | ||||||||||||||||||||||
Total insulin | 42,923 | 29,431 | 13,982 | 8,523 | 6,926 | 13,492 | 12,704 | ||||||||||||||||||||||
% change at CER | (3%) | 10% | 6% | 14% | 12% | (22%) | (23%) | ||||||||||||||||||||||
Victoza®
|
13,990 | 5,578 | 3,371 | 795 | 1,412 | 8,412 | 8,137 | ||||||||||||||||||||||
% change at CER | (15%) | 5% | (6%) | 23% | 29% | (24%) | (24%) | ||||||||||||||||||||||
Ozempic®
|
15,023 | 2,493 | 2,160 | 4 | 329 | 12,530 | 11,839 | ||||||||||||||||||||||
% change at CER | 120% | 303% | 304% | — | 292% | 101% | 101% | ||||||||||||||||||||||
Rybelsus®
|
1,038 | 16 | 16 | — | — | 1,022 | 1,015 | ||||||||||||||||||||||
% change at CER | — | — | — | — | — | — | — | ||||||||||||||||||||||
Total GLP-1 | 30,051 | 8,087 | 5,547 | 799 | 1,741 | 21,964 | 20,991 | ||||||||||||||||||||||
% change at CER | 29% | 37% | 35% | 24% | 51% | 27% | 26% | ||||||||||||||||||||||
Other Diabetes care1
|
3,056 | 2,250 | 547 | 1,204 | 499 | 806 | 701 | ||||||||||||||||||||||
% change at CER | (4%) | (12%) | (31%) | (5%) | (2%) | 31% | 38% | ||||||||||||||||||||||
Total Diabetes care | 76,030 | 39,768 | 20,076 | 10,526 | 9,166 | 36,262 | 34,396 | ||||||||||||||||||||||
% change at CER | 8% | 13% | 11% | 12% | 17% | 3% | 2% | ||||||||||||||||||||||
Obesity care (Saxenda®)
|
4,223 | 1,611 | 834 | 6 | 771 | 2,612 | 2,420 | ||||||||||||||||||||||
% change at CER | 6% | 8% | 8% | (17%) | 7% | 4% | 4% | ||||||||||||||||||||||
Diabetes and Obesity care total | 80,253 | 41,379 | 20,910 | 10,532 | 9,937 | 38,874 | 36,816 | ||||||||||||||||||||||
% change at CER | 8% | 12% | 11% | 12% | 16% | 3% | 2% | ||||||||||||||||||||||
Biopharm segment | |||||||||||||||||||||||||||||
Haemophilia2
|
7,522 | 4,513 | 2,864 | 257 | 1,392 | 3,009 | 2,794 | ||||||||||||||||||||||
% change at CER | (2%) | 3% | 8% | 14% | (8%) | (7%) | (7%) | ||||||||||||||||||||||
NovoSeven®
|
5,683 | 3,222 | 1,920 | 247 | 1,055 | 2,461 | 2,364 | ||||||||||||||||||||||
% change at CER | (7%) | (4%) | 3% | 17% | (17%) | (10%) | (9%) | ||||||||||||||||||||||
NovoEight®
|
1,115 | 856 | 616 | 10 | 230 | 259 | 242 | ||||||||||||||||||||||
% change at CER | 1% | 2% | (4%) | (23%) | 20% | 1% | 1% | ||||||||||||||||||||||
Growth disorders (Norditropin®)
|
5,872 | 3,676 | 1,705 | 42 | 1,929 | 2,196 | 2,183 | ||||||||||||||||||||||
% change at CER | 13% | 18% | 17% | 72% | 18% | 7% | 7% | ||||||||||||||||||||||
Other Biopharm3
|
1,161 | 831 | 680 | 5 | 146 | 330 | 154 | ||||||||||||||||||||||
% change at CER | 1% | 1% | 2% | (20%) | (3%) | 1% | 2% | ||||||||||||||||||||||
Biopharm total | 14,555 | 9,020 | 5,249 | 304 | 3,467 | 5,535 | 5,131 | ||||||||||||||||||||||
% change at CER | 4% | 8% | 10% | 19% | 5% | (2%) | (2%) | ||||||||||||||||||||||
Total sales | 94,808 | 50,399 | 26,159 | 10,836 | 13,404 | 44,409 | 41,947 | ||||||||||||||||||||||
% change at CER | 7% | 12% | 11% | 12% | 13% | 2% | 2% | ||||||||||||||||||||||
% change as reported | 6% | 9% | 9% | 10% | 8% | 2% | 2% | ||||||||||||||||||||||
Share of growth | 100% | 83% | 39% | 19% | 25% | 17% | 11% | ||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 30 of 33
|
Sales at CER | |||||||||||||||||||||||
DKK million | 9M 2020 | 9M 2019 |
% change
9M 2020 to 9M 2019 |
Q3 2020 | Q3 2019 |
% change
Q3 2020 to Q3 2019 |
|||||||||||||||||
Net sales | 94,808 | 89,604 | 6 | % | 30,927 | 30,277 | 2 | % | |||||||||||||||
Effect of exchange rates | 1,209 | — | 1,591 | — | |||||||||||||||||||
Sales at CER | 96,017 | 89,604 | 7 | % | 32,518 | 30,277 | 7 | % | |||||||||||||||
Operating profit at CER | |||||||||||||||||||||||
DKK million | 9M 2020 | 9M 2019 |
% change
9M 2020 to 9M 2019 |
Q3 2020 | Q3 2019 |
% change
Q3 2020 to Q3 2019 |
|||||||||||||||||
Operating profit | 42,948 | 40,610 | 6 | % | 12,808 | 12,919 | (1 | %) | |||||||||||||||
Effect of exchange rates | 680 | — | 983 | — | |||||||||||||||||||
Operating profit at CER | 43,628 | 40,610 | 7 | % | 13,791 | 12,919 | 7 | % |
Free cash flow | ||||||||||||||
DKK million | 9M 2020 | 9M 2019 | Q3 2020 | Q3 2019 | ||||||||||
Net cash generated from operating activities | 51,779 | 41,617 | 17,506 | 16,688 | ||||||||||
Net cash used in investing activities | (9,536) | (8,300) | (6,063) | (2,441) | ||||||||||
Repayment on lease liabilities | (684) | (603) | (219) | (208) | ||||||||||
Free cash flow | 41,559 | 32,714 | 11,224 | 14,039 |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 31 of 33
|
Financial resources | ||||||||
DKK million | 9M 2020 | Q4 2019 | ||||||
Cash and cash equivalents | 25,465 | 15,411 | ||||||
Undrawn committed credit facilities | 11,542 | 11,578 | ||||||
Borrowings (bank overdrafts) | (595) | (595) | ||||||
Financial resources | 36,412 | 26,394 |
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 32 of 33
|
Q3 2019 sales split per area - DKK million | Total |
International
Operations |
EMEA |
Region
China |
Rest of
World |
North America
Operations |
The US | ||||||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||||||||
Long-acting insulin | 5,019 | 2,266 | 1,434 | 289 | 543 | 2,753 | 2,630 | ||||||||||||||||||||||
Tresiba®
|
2,306 | 888 | 486 | 27 | 375 | 1,418 | 1,343 | ||||||||||||||||||||||
Xultophy®
|
575 | 370 | 343 | — | 27 | 205 | 202 | ||||||||||||||||||||||
Levemir®
|
2,138 | 1,008 | 605 | 262 | 141 | 1,130 | 1,085 | ||||||||||||||||||||||
Premix insulin | 2,596 | 2,479 | 781 | 1,095 | 603 | 117 | 109 | ||||||||||||||||||||||
Ryzodeg®
|
278 | 278 | 69 | — | 209 | — | — | ||||||||||||||||||||||
NovoMix®
|
2,318 | 2,201 | 712 | 1,095 | 394 | 117 | 109 | ||||||||||||||||||||||
Fast-acting insulin | 4,632 | 2,536 | 1,524 | 463 | 549 | 2,096 | 1,989 | ||||||||||||||||||||||
Fiasp®
|
301 | 164 | 150 | — | 14 | 137 | 129 | ||||||||||||||||||||||
NovoRapid®
|
4,331 | 2,372 | 1,374 | 463 | 535 | 1,959 | 1,860 | ||||||||||||||||||||||
Human insulin | 2,237 | 1,799 | 610 | 706 | 483 | 438 | 406 | ||||||||||||||||||||||
Total insulin | 14,484 | 9,080 | 4,349 | 2,553 | 2,178 | 5,404 | 5,134 | ||||||||||||||||||||||
Victoza®
|
5,370 | 1,741 | 1,157 | 227 | 357 | 3,629 | 3,507 | ||||||||||||||||||||||
Ozempic®
|
3,122 | 326 | 285 | — | 41 | 2,796 | 2,659 | ||||||||||||||||||||||
Rybelsus®
|
— | — | — | — | — | — | — | ||||||||||||||||||||||
Total GLP-1 | 8,492 | 2,067 | 1,442 | 227 | 398 | 6,425 | 6,166 | ||||||||||||||||||||||
Other Diabetes care | 1,038 | 819 | 262 | 387 | 170 | 219 | 178 | ||||||||||||||||||||||
Total Diabetes care | 24,014 | 11,966 | 6,053 | 3,167 | 2,746 | 12,048 | 11,478 | ||||||||||||||||||||||
Obesity care (Saxenda®) | 1,442 | 514 | 239 | 2 | 273 | 928 | 865 | ||||||||||||||||||||||
Diabetes and Obesity care total | 25,456 | 12,480 | 6,292 | 3,169 | 3,019 | 12,976 | 12,343 | ||||||||||||||||||||||
Biopharm segment | |||||||||||||||||||||||||||||
Haemophilia | 2,524 | 1,441 | 928 | 78 | 435 | 1,083 | 1,020 | ||||||||||||||||||||||
NovoSeven®
|
1,985 | 1,083 | 667 | 74 | 342 | 902 | 880 | ||||||||||||||||||||||
NovoEight®
|
357 | 268 | 204 | 4 | 60 | 89 | 82 | ||||||||||||||||||||||
Growth disorders (Norditropin®) | 1,886 | 1,051 | 461 | 10 | 580 | 835 | 833 | ||||||||||||||||||||||
Other Biopharm | 411 | 289 | 232 | 1 | 56 | 122 | 60 | ||||||||||||||||||||||
Biopharm total | 4,821 | 2,781 | 1,621 | 89 | 1,071 | 2,040 | 1,913 | ||||||||||||||||||||||
Total sales | 30,277 | 15,261 | 7,913 | 3,258 | 4,090 | 15,016 | 14,256 | ||||||||||||||||||||||
9M 2019 sales split per area - DKK million | Total |
International
Operations |
EMEA |
Region
China |
Rest of
World |
North America
Operations |
The US | ||||||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||||||||
Long-acting insulin | 15,674 | 6,783 | 4,454 | 820 | 1,509 | 8,891 | 8,556 | ||||||||||||||||||||||
Tresiba®
|
6,948 | 2,593 | 1,485 | 58 | 1,050 | 4,355 | 4,164 | ||||||||||||||||||||||
Xultophy®
|
1,626 | 1,080 | 1,021 | — | 59 | 546 | 540 | ||||||||||||||||||||||
Levemir®
|
7,100 | 3,110 | 1,948 | 762 | 400 | 3,990 | 3,852 | ||||||||||||||||||||||
Premix insulin | 7,913 | 7,376 | 2,381 | 3,286 | 1,709 | 537 | 513 | ||||||||||||||||||||||
Ryzodeg®
|
747 | 747 | 184 | 1 | 562 | — | — | ||||||||||||||||||||||
NovoMix®
|
7,166 | 6,629 | 2,197 | 3,285 | 1,147 | 537 | 513 | ||||||||||||||||||||||
Fast-acting insulin | 14,367 | 7,732 | 4,773 | 1,353 | 1,606 | 6,635 | 6,334 | ||||||||||||||||||||||
Fiasp®
|
804 | 444 | 416 | — | 28 | 360 | 339 | ||||||||||||||||||||||
NovoRapid®
|
13,563 | 7,288 | 4,357 | 1,353 | 1,578 | 6,275 | 5,995 | ||||||||||||||||||||||
Human insulin | 6,832 | 5,628 | 1,834 | 2,170 | 1,624 | 1,204 | 1,110 | ||||||||||||||||||||||
Total insulin | 44,786 | 27,519 | 13,442 | 7,629 | 6,448 | 17,267 | 16,513 | ||||||||||||||||||||||
Victoza®
|
16,507 | 5,378 | 3,579 | 655 | 1,144 | 11,129 | 10,776 | ||||||||||||||||||||||
Ozempic®
|
6,872 | 641 | 536 | — | 105 | 6,231 | 5,900 | ||||||||||||||||||||||
Rybelsus®
|
— | — | — | — | — | — | — | ||||||||||||||||||||||
Total GLP-1 | 23,379 | 6,019 | 4,115 | 655 | 1,249 | 17,360 | 16,676 | ||||||||||||||||||||||
Other Diabetes care | 3,230 | 2,611 | 808 | 1,280 | 523 | 619 | 509 | ||||||||||||||||||||||
Total Diabetes care | 71,395 | 36,149 | 18,365 | 9,564 | 8,220 | 35,246 | 33,698 | ||||||||||||||||||||||
Obesity care (Saxenda®) | 4,115 | 1,611 | 781 | 6 | 824 | 2,504 | 2,323 | ||||||||||||||||||||||
Diabetes and Obesity care total | 75,510 | 37,760 | 19,146 | 9,570 | 9,044 | 37,750 | 36,021 | ||||||||||||||||||||||
Biopharm segment | |||||||||||||||||||||||||||||
Haemophilia | 7,727 | 4,475 | 2,683 | 225 | 1,567 | 3,252 | 3,012 | ||||||||||||||||||||||
NovoSeven®
|
6,160 | 3,413 | 1,895 | 212 | 1,306 | 2,747 | 2,610 | ||||||||||||||||||||||
NovoEight®
|
1,119 | 863 | 645 | 13 | 205 | 256 | 239 | ||||||||||||||||||||||
Growth disorders (Norditropin®) | 5,199 | 3,140 | 1,467 | 25 | 1,648 | 2,059 | 2,049 | ||||||||||||||||||||||
Other Biopharm | 1,168 | 838 | 681 | 5 | 152 | 330 | 152 | ||||||||||||||||||||||
Biopharm total | 14,094 | 8,453 | 4,831 | 255 | 3,367 | 5,641 | 5,213 | ||||||||||||||||||||||
Total sales | 89,604 | 46,213 | 23,977 | 9,825 | 12,411 | 43,391 | 41,234 | ||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
Financial report for the period 1 January 2020 to 30 September 2020 |
Page 33 of 33
|
2019 sales split per area - DKK million | Total |
International
Operations |
EMEA |
Region
China |
Rest of
World |
North America
Operations |
The US | ||||||||||||||||||||||
Diabetes and Obesity care segment | |||||||||||||||||||||||||||||
Long-acting insulin | 20,776 | 9,035 | 5,955 | 1,059 | 2,021 | 11,741 | 11,271 | ||||||||||||||||||||||
Tresiba®
|
9,259 | 3,477 | 1,983 | 87 | 1,407 | 5,782 | 5,500 | ||||||||||||||||||||||
Xultophy®
|
2,210 | 1,493 | 1,407 | — | 86 | 717 | 708 | ||||||||||||||||||||||
Levemir®
|
9,307 | 4,065 | 2,565 | 972 | 528 | 5,242 | 5,063 | ||||||||||||||||||||||
Premix insulin | 10,578 | 9,707 | 3,160 | 4,306 | 2,241 | 871 | 839 | ||||||||||||||||||||||
Ryzodeg®
|
993 | 993 | 237 | 4 | 752 | — | — | ||||||||||||||||||||||
NovoMix®
|
9,585 | 8,714 | 2,923 | 4,302 | 1,489 | 871 | 839 | ||||||||||||||||||||||
Fast-acting insulin | 19,303 | 10,304 | 6,422 | 1,753 | 2,129 | 8,999 | 8,592 | ||||||||||||||||||||||
Fiasp®
|
1,243 | 617 | 585 | — | 32 | 626 | 597 | ||||||||||||||||||||||
NovoRapid®
|
18,060 | 9,687 | 5,837 | 1,753 | 2,097 | 8,373 | 7,995 | ||||||||||||||||||||||
Human insulin | 9,036 | 7,361 | 2,438 | 2,847 | 2,076 | 1,675 | 1,552 | ||||||||||||||||||||||
Total insulin | 59,693 | 36,407 | 17,975 | 9,965 | 8,467 | 23,286 | 22,254 | ||||||||||||||||||||||
Victoza®
|
21,934 | 7,249 | 4,713 | 898 | 1,638 | 14,685 | 14,217 | ||||||||||||||||||||||
Ozempic®
|
11,237 | 1,143 | 969 | — | 174 | 10,094 | 9,599 | ||||||||||||||||||||||
Rybelsus®
|
50 | — | — | — | — | 50 | 50 | ||||||||||||||||||||||
Total GLP-1 | 33,221 | 8,392 | 5,682 | 898 | 1,812 | 24,829 | 23,866 | ||||||||||||||||||||||
Other Diabetes care | 4,247 | 3,389 | 1,052 | 1,647 | 690 | 858 | 705 | ||||||||||||||||||||||
Total Diabetes care | 97,161 | 48,188 | 24,709 | 12,510 | 10,969 | 48,973 | 46,825 | ||||||||||||||||||||||
Obesity care (Saxenda®) | 5,679 | 2,083 | 981 | 9 | 1,093 | 3,596 | 3,348 | ||||||||||||||||||||||
Diabetes and Obesity care total | 102,840 | 50,271 | 25,690 | 12,519 | 12,062 | 52,569 | 50,173 | ||||||||||||||||||||||
Biopharm segment | |||||||||||||||||||||||||||||
Haemophilia | 10,281 | 5,946 | 3,646 | 284 | 2,016 | 4,335 | 4,031 | ||||||||||||||||||||||
NovoSeven®
|
8,119 | 4,502 | 2,577 | 269 | 1,656 | 3,617 | 3,454 | ||||||||||||||||||||||
NovoEight®
|
1,525 | 1,143 | 844 | 15 | 284 | 382 | 358 | ||||||||||||||||||||||
Growth disorders (Norditropin®) | 7,275 | 4,225 | 1,960 | 36 | 2,229 | 3,050 | 3,035 | ||||||||||||||||||||||
Other Biopharm | 1,625 | 1,122 | 912 | 5 | 205 | 503 | 247 | ||||||||||||||||||||||
Biopharm total | 19,181 | 11,293 | 6,518 | 325 | 4,450 | 7,888 | 7,313 | ||||||||||||||||||||||
Total sales | 122,021 | 61,564 | 32,208 | 12,844 | 16,512 | 60,457 | 57,486 | ||||||||||||||||||||||
COVID-19 | Strategic aspirations |
Financial
Performance |
Equity and capital allocation | Outlook | R&D | Sustainability | Corporate governance | Financial Information | |||||||||||||||||||||
Company announcement No 63 / 2020 |
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions